Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ISM5411 (NCT07265570), which has recently been granted the generic name of Garutadustat by the United States Adopted Names (USAN) Council. Garutadustat (originally ISM5411) is a novel, gut-restricted PHD inhibitor developed with Pharma.AI, Insilico’s generative platform, for the treatment of Inflammatory Bowel Disease (IBD). 

New research shows that adolescents who were overweight, struggled to make friends, were born outside the U.S., or faced mental health challenges such as anxiety, depression, ADD/ADHD or learning disabilities were at greater risk of involvement in bullying, either as victims, perpetrators or both. The findings reveal a troubling cycle, underscoring the need for prevention efforts that address the social, family, and health-related factors shaping adolescent behavior.

Smoking tobacco is known to worsen symptoms of periodontitis and reduce responsiveness to treatment. Using high-resolution spatial transcriptomics, researchers identified differences between smokers and non-smokers in the expression of genes that weaken gum epithelial integrity and cause bone damage through inflammation. They also identified CXCL12 secreted by endothelial cells in gums as a crucial mediator of immune-cell recruitment that drives excessive inflammation. CXCL12 is a possible target for new therapies against periodontitis aggravated by smoking.